NuCana (NCNA) Income from Continuing Operations (2017 - 2025)
NuCana (NCNA) reported Income from Continuing Operations of 3683230.2 for Q4 2025, down 209.57% on a YoY basis from 3361667.95 in Q4 2024, and down 181.11% sequentially from 1310230.65 in Q3 2025.
NuCana (NCNA) Income from Continuing Operations (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Income from Continuing Operations data on file, last reported at 3683230.2 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 209.57% year-over-year to 3683230.2; the trailing twelve-month figure through Dec 2025 stood at 42041724.68 (down 27.4% YoY), and the FY2025 full-year result was 41782274.03, down 26.18% from the prior year.
- Income from Continuing Operations slipped to 3683230.2 in Q4 2025, from 1310230.65 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1189806.21 in Q4 2024 to a low of 33044311.61 in Q2 2025.
- A 5-year average of 12563324.61 and a median of 12011766.03 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 90.68% in 2024 and tumbled 209.57% in 2025, its largest moves.
- Tracing NCNA's Income from Continuing Operations over 5 years: stood at 23975716.66 in 2021, then advanced by 8.42% to 21956045.24 in 2022, then surged by 41.86% to 12765247.14 in 2023, then surged by 90.68% to 1189806.21 in 2024, then plunged by 209.57% to 3683230.2 in 2025.
- Business Quant data shows NCNA's Income from Continuing Operations at 3683230.2 in Q4 2025, 1310230.65 in Q3 2025, and 33044311.61 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | NuCana | 14.60 Bn | 14.60 Bn | - | -3.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.68 Mn |
| Sep 30, 2025 | -1.31 Mn |
| Jun 30, 2025 | -33.04 Mn |
| Mar 31, 2025 | -4.00 Mn |
| Dec 31, 2024 | -1.19 Mn |
| Sep 30, 2024 | -7.78 Mn |
| Jun 30, 2024 | -12.04 Mn |
| Mar 31, 2024 | -11.98 Mn |
| Dec 31, 2023 | -12.77 Mn |
| Sep 30, 2023 | -12.04 Mn |
| Jun 30, 2023 | -8.49 Mn |
| Mar 31, 2023 | -11.98 Mn |
| Dec 31, 2022 | -21.96 Mn |
| Sep 30, 2022 | -8.74 Mn |
| Jun 30, 2022 | -7.91 Mn |
| Mar 31, 2022 | -16.73 Mn |
| Dec 31, 2021 | -23.98 Mn |
| Sep 30, 2021 | -16.35 Mn |
| Jun 30, 2021 | -17.13 Mn |
| Mar 31, 2021 | -18.15 Mn |